UroToday4d
Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer.
We aim to determine the prognostic significance of glutathione S-transferase Pi 1 DNA methylation (mGSTP1) in two independent prostate cancer cohorts with long-term clinical follow-up data. We first ...
UroToday3d
Predicting Response to Bipolar Androgen Therapy (BAT) - A Blood-Based Biomarker Approach
Alicia Morgans interviews Samuel Denmeade about the TRANSFORMER trial and Bipolar Androgen Therapy (BAT) for prostate cancer. Dr. Denmeade explains that the trial, involving 200 patients, compared ...
UroToday4d
Selective treatment de-escalation in advanced prostate cancer: have we come full circle?
Compelling evidence has solidified the notion of early treatment intensification in managing patients with metastatic hormone-sensitive prostate cancer (mHSPC). Landmark trials have provided Level 1 ...
UroToday4d
Differential expression of metabolic enzymes in testicular germ cell tumors: The impact of glycolytic metabolism in embryonal carcinoma histotype.
Testicular germ cell tumors are the most common solid malignancies in young men, with increasing incidence worldwide. Broadly classified into seminomas and non-seminomas, they exhibit distinct ...
UroToday4d
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma.
Immune Checkpoints Inhibitors (ICI) have changed the therapeutic landscape of metastatic renal cell carcinoma first-line treatment with complete response (CR) at metastatic sites observed in 10 to 15% ...
UroToday4d
Incidence and Survival of Patients With Prostate Cancer in North-Rhine Westphalia, Germany.
There is no organized prostate cancer screening in Germany. The aim of this study was to investigate the development of incidence and survival in patients with primary malignant tumors of the prostate ...
UroToday4d
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer.
Adverse pathology (AP) is often used as an intermediate end point for long-term outcomes in men with prostate cancer (PCa) who are active surveillance candidates. The association between a commonly ...
UroToday3d
ASCO GU 2023: ZIRCON: Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma
(UroToday.com) The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Brian Shuch discussing results from ZIRCON, a phase 3 ...
UroToday3d
EAU 2023: 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma - Results from Phase 3 ZIRCON Study
(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10 th and 13 th, 2023 was host to a game changing session. Professor Peter Mulders ...
UroToday6d
Bipolar Androgen Therapy: Rationale, Candidate Patients, and Latest Evidence for mCRPC Patients
Androgen receptor inhibition remains the mainstay treatment of advanced prostate cancer. However, therapeutic resistance to androgen receptor inhibition is almost universal. Prostate cancer cells can ...
UroToday3d
SUO 2024: Implementing Smoking Cessation in the Urologic Oncology Setting
(UroToday.com) The 2024 SUO annual meeting included a session on smoking cessation, vaping, and e-cigarettes, featuring a presentation by Dr. Richard Matulewicz discussing implementing smoking ...
UroToday3d
SUO 2024: Adjuvant Radiation Following Cystectomy: Underutilized Therapy?
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to an Advanced Disease and Adjuvant Therapy session. Dr. Omar Mian discussed the role of adjuvant ...